Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Daily

Download Data

Edgewise Therapeutics Inc Market Capitalization on June 03, 2024: USD 1.63 B

Edgewise Therapeutics Inc Market Capitalization is USD 1.63 B on June 03, 2024, a 103.32% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Edgewise Therapeutics Inc 52-week high Market Capitalization is USD 1.98 B on May 07, 2024, which is 21.96% above the current Market Capitalization.
Edgewise Therapeutics Inc 52-week low Market Capitalization is USD 1.41 M on May 06, 2024, which is -99.91% below the current Market Capitalization.
Edgewise Therapeutics Inc average Market Capitalization for the last 52 weeks is USD 974.88 M.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends